Evidence map›Paper›PMID 35740492›Full record

ReviewCancers2022

Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target.

Eiji Kobayashi, Satoru Kondo, Hirotomo Dochi, Makiko Moriyama-Kita, Nobuyuki Hirai, Takeshi Komori, Takayoshi Ueno, Yosuke Nakanishi, Miyako Hatano, Kazuhira Endo and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Eiji KobayashiDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.ORCID 0000-0001-7318-8057
Satoru KondoDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Hirotomo DochiDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Makiko Moriyama-KitaDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Nobuyuki HiraiDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Takeshi KomoriDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Takayoshi UenoDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Yosuke NakanishiDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Miyako HatanoDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Kazuhira EndoDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Hisashi SugimotoDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Naohiro WakisakaDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Tomokazu YoshizakiDepartment of Otolaryngology-Head and Neck Surgery, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
Kanazawa University · JP

Funding

Japan Society for the Promotion of Science 21K20946
6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is one of the Epstein-Barr virus (EBV)-associated malignancies. NPC is highly metastatic compared to other head and neck carcinomas, and evidence has shown that the metastatic features of NPC are involved in EBV infection. The prognosis of advanced cases, especially those with distant metastasis, is still poor despite advancements in molecular research and its application to clinical settings. Thus, further advancement in basic and clinical research that may lead to novel therapeutic modalities is needed. Farnesylation is a lipid modification in the C-terminus of proteins. It enables proteins to attach to the lipid bilayer structure of cellular membranes. Farnesylation was initially identified as a key process of membrane association and activation of the RAS oncoprotein. Farnesylation is thus expected to be an ideal therapeutic target in anti-RAS therapy. Additionally, more and more molecular evidence has been reported, showing that proteins other than RAS are also farnesylated and have significant roles in cancer progression. However, although several clinical trials have been conducted in cancers with high rates of

Indexed as

Epstein–Barr virusfarnesylationfarnesyltransferase inhibitornasopharyngeal carcinomaRAS

Identifiers

PMID35740492
PMCPMC9220992
OpenAlexW4281626911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.